Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
None
ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy

Pulmonary Arterial Hypertension or PAH is a progressive condition for which there is no cure. Even with substantial pharmacologic advances in the modern treatment era, survival still remains unacceptably poor, as reported in large PAH registries. Preclinical studies suggest that the administration of allogeneic CDCs have the potential to reduce …

  • 99 views
  • 25 Mar, 2021
  • 1 location
None
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis

HSCT has been implemented in (inter)national treatment guidelines for diffuse cutaneous systemic sclerosis (dcSSc) and is offered in clinical care and reimbursed by national health insurance in

  • 0 views
  • 18 Apr, 2021
  • 14 locations
None
Study to Evaluate Efficacy Safety and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

To evaluate the efficacy of MT-7117 treatment in subjects with diffuse cutaneous systemic sclerosis (dcSSc) using the American College of Rheumatology Composite Response Index in Diffuse

  • 2 views
  • 05 Dec, 2021
  • 43 locations
None
  • 63 views
  • 22 Apr, 2021
  • 1 location
None
KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

This randomized, placebo-controlled phase 2 study is seeking to evaluate the efficacy and safety of belumosudil (KD025) for the treatment of diffuse cutaneous systematic sclerosis. Upon eligibility confirmation, a total of 60 adult subjects will be enrolled and randomized into 3 groups (1:1:1) to either receive orally administered belumosudil (200 …

MRSS
platelet count
methotrexate
progressive systemic sclerosis
raynaud's syndrome
  • 201 views
  • 16 Nov, 2021
  • 36 locations
None
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).

systemic sclerosis
heart failure
progressive systemic sclerosis
raynaud's syndrome
ifetroban
  • 0 views
  • 27 Sep, 2021
  • 17 locations
None
Evaluation of Safety Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with diffuse cutaneous Systemic Sclerosis (dcSSc).

  • 7 views
  • 27 Oct, 2021
  • 21 locations
None
Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

This is a 52 week, single center, randomized, double-blind, placebo-controlled study. After patients maintain a stable dose of Mycophenolate Mofetil (MMF) for at least 1 month, they will be randomized to treatment with either Belimumab & Rituximab or placebo.Patients in both groups will be on background MMF for the entirety …

MRSS
arthritis
progressive systemic sclerosis
raynaud's syndrome
immunosuppressive agents
  • 29 views
  • 10 Oct, 2021
  • 1 location
None
A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

), a fully human monoclonal antibody (mAb) inhibitor of the IGF-1 receptor (IGF-1R), administered once every 3 weeks (q3W) for 24 weeks in the treatment of participants with diffuse cutaneous systemic

  • 0 views
  • 03 Sep, 2021
  • 3 locations
None
Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis

This is a phase 2, open-label, single-cohort, multicenter trial of belumosudil in subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc). An estimated total of 12 to 15 subjects will receive

  • 0 views
  • 25 Sep, 2021
  • 6 locations